Difference between revisions of "Pharm Tech Minutes 2021.06.23"
Jump to navigation
Jump to search
Michael tan (talk | contribs) |
Michael tan (talk | contribs) |
||
| (9 intermediate revisions by the same user not shown) | |||
| Line 16: | Line 16: | ||
== Medication lists == | == Medication lists == | ||
| − | * Sandbox Belgium | + | * Focus on the Sandbox which Jose has used for Belgium |
* A patient has a treatment plan. This could initiated by the patient, but more often it could be a plan from a Care Provider. | * A patient has a treatment plan. This could initiated by the patient, but more often it could be a plan from a Care Provider. | ||
* There could be multiple plans from different care providers. | * There could be multiple plans from different care providers. | ||
| − | * The diagram is actually treatment | + | * The diagram is actually treatment. |
| − | * Agreement that there is a treatment, but difference is where to draw the line. | + | * Agreement in the group that there is a treatment, but difference is where to draw the line. |
| − | * | + | * The rules where to find the correct dosage will depend on the settings in the different countries. |
| − | + | * Rules to the period will differ per country. A current medication summary in NL& F means the last 6 months. In Switzerland it is what the patient is using now. Point is that we would like to define the differences. | |
| − | * | + | * Within FHIR it makes it easier to map to another format from another country. The IHE profile would make the mapping much easier. |
| − | * Within FHIR it makes it easier to map to another format from another country. | + | * The IPS is just a collection of medication statements. |
| + | * We should not use the same name as IPS. Suggestion to use '''medication view'''. | ||
| + | * Indication is mentioned on different levels. It also depends on the setting where to mention the indication. | ||
| + | |||
| + | * Action items for the F2F in September: | ||
| + | ** generic guidelines to be written ( Stephane) | ||
| + | ** Mapping to different country settings. Belgium, Switzerland, Netherlands, France, Austria. (all other members) | ||
== Any other business == | == Any other business == | ||
| + | |||
| + | * Links: | ||
| + | ** http://build.fhir.org/ig/hl7-be/riziv-inami/artifacts.html | ||
| + | ** http://build.fhir.org/ig/hl7-be/riziv-medication-record/medicationrecord-fhir-resources.html | ||
Latest revision as of 05:00, 25 June 2021
Minutes
Welcome
- Participants
- Jose Costa Teixeira
- Stephane Spahni
- Michael Tan
- Juergen Brandstaetter
- Marc Robberecht
- Review and Approve Agenda
Medication lists
- Focus on the Sandbox which Jose has used for Belgium
- A patient has a treatment plan. This could initiated by the patient, but more often it could be a plan from a Care Provider.
- There could be multiple plans from different care providers.
- The diagram is actually treatment.
- Agreement in the group that there is a treatment, but difference is where to draw the line.
- The rules where to find the correct dosage will depend on the settings in the different countries.
- Rules to the period will differ per country. A current medication summary in NL& F means the last 6 months. In Switzerland it is what the patient is using now. Point is that we would like to define the differences.
- Within FHIR it makes it easier to map to another format from another country. The IHE profile would make the mapping much easier.
- The IPS is just a collection of medication statements.
- We should not use the same name as IPS. Suggestion to use medication view.
- Indication is mentioned on different levels. It also depends on the setting where to mention the indication.
- Action items for the F2F in September:
- generic guidelines to be written ( Stephane)
- Mapping to different country settings. Belgium, Switzerland, Netherlands, France, Austria. (all other members)